Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
, 17 (1), 438

Early Experiences From One of the First Treatment Programs for Chronic Hepatitis B in sub-Saharan Africa

Affiliations
Clinical Trial

Early Experiences From One of the First Treatment Programs for Chronic Hepatitis B in sub-Saharan Africa

Hanna Aberra et al. BMC Infect Dis.

Abstract

Background: Treatment for chronic hepatitis B (CHB) is virtually absent in sub-Saharan Africa. Here we present early experiences from a pilot program for treatment of CHB in Ethiopia.

Methods: Adults (≥18 years) with CHB were included in a cohort study at St. Paul's Hospital Millennium Medical College, Addis Ababa, from February 2015. The baseline assessment included liver function tests, viral markers and transient elastography (Fibroscan 402, Echosense, France). Logistic regression models were used to identify predictors of fibrosis. Tenofovir disoproxil fumarate (TDF) was initiated based on the European Association for the Study of the Liver (EASL) criteria, with some modifications. The initial 300 patients underwent a more comprehensive evaluation and are presented here.

Results: One-hundred-and-thirty-eight patients (46.0%) were women and median age was 30 years (interquartile range 26-40). Co-infections were rare: four patients (1.3%) were anti-HCV positive, 11 (3.7%) were anti-HDV positive, whereas 5 (1.7%) had HIV-infection. The majority were hepatitis B e-antigen (HBeAg) negative (n = 262; 90.7%) and had a normal (≤40 U/L) alanine aminotransferase (ALT) (n = 245; 83.1%). Of 268 patients with a valid Fibroscan result, 79 (29.5%) had significant fibrosis (>7.9 kPa). Independent predictors of fibrosis were male sex, age > 35 years and viral load >20,000 IU/ml. In total, 74 patients (24.7%) started TDF therapy, of whom 46 (62.2%) had cirrhosis.

Conclusions: The majority were HBeAg negative and had normal ALT. However, one quarter of the patients were in need of antiviral treatment, underscoring the need to scale up CHB treatment on the African continent.

Trial registration: NCT02344498 ( ClinicalTrials.gov identifier). Registered 16 January 2015.

Keywords: Africa; Antiviral therapy; Hepatitis B virus; Resource-limited settings.

Figures

Fig. 1
Fig. 1
Liver fibrosis as a function of a sex, b age, c ALT and d HBV viral load in a cohort of patients with chronic hepatitis B in Ethiopia. Patients with invalid/missing Fibroscan results or ALT elevated more than 5 times the upper limit of normal were excluded from this analysis

Similar articles

See all similar articles

Cited by 7 articles

See all "Cited by" articles

References

    1. World Health Organization . Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. Geneva: WHO; 2015.
    1. European Association for the Study of the Liver EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57(1):167–185. doi: 10.1016/j.jhep.2012.02.010. - DOI - PubMed
    1. World Health Organization. Global health sector strategy on viral hepatitis. Towards ending viral hepatitis. Geneva: WHO; 2016.
    1. Pol S, Lampertico P. First-line treatment of chronic hepatitis B with entecavir or tenofovir in 'real-life' settings: from clinical trials to clinical practice. J Viral Hepat. 2012;19(6):377–386. doi: 10.1111/j.1365-2893.2012.01602.x. - DOI - PMC - PubMed
    1. Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381(9865):468–475. doi: 10.1016/S0140-6736(12)61425-1. - DOI - PubMed

Publication types

MeSH terms

Associated data

Feedback